Technical Analysis for EVAX - Evaxion Biotech A/S

Grade Last Price % Change Price Change
F 6.96 -6.07% -0.45
EVAX closed down 6.07 percent on Friday, February 26, 2021, on 22 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical EVAX trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Hot IPO Pullback Bullish Swing Setup -6.07%
Hot IPO Pullback Bullish Swing Setup -7.20%
Inside Day Range Contraction -7.20%
New 52 Week Closing Low Bearish -4.40%
Hot IPO Pullback Bullish Swing Setup -4.40%
New 52 Week Low Weakness -4.40%
Down 3 Days in a Row Weakness -4.40%
Gapped Down Weakness -4.40%
Older End-of-Day Signals for EVAX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Evaxion Biotech A/S Description

Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate. Evaxion Biotech A/S was founded in 2008 and is headquartered in Copenhagen, Denmark.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Artificial Intelligence Immunotherapy Surgery Cancers Cancer Immunotherapy Non Small Cell Lung Cancer Melanoma Genomics Immunotherapies Medical Genetics Vaccination Bladder Cancer Viral Disease Bacterial Diseases Cancer Vaccines Viral Infections Hernia Treatment Of Various Cancers Dna Based Cancer

Is EVAX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.34
52 Week Low 6.77
Average Volume 143,787
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 8.06
Average True Range 0.73
ADX 0.0
+DI 5.18
-DI 32.49
Chandelier Exit (Long, 3 ATRs ) 8.15
Chandelier Exit (Short, 3 ATRs ) 8.96
Upper Bollinger Band 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line -0.39
MACD Signal Line -0.16
MACD Histogram -0.2287
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.65
Resistance 3 (R3) 7.73 7.57 7.54
Resistance 2 (R2) 7.57 7.40 7.54 7.50
Resistance 1 (R1) 7.27 7.29 7.19 7.19 7.46
Pivot Point 7.11 7.11 7.08 7.08 7.11
Support 1 (S1) 6.81 6.94 6.73 6.73 6.46
Support 2 (S2) 6.65 6.83 6.62 6.42
Support 3 (S3) 6.35 6.65 6.39
Support 4 (S4) 6.27